A wearable pain relief device is set to hit store shelves, thanks to NeuroMetrix's distribution agreement with Advantage Consumer Healthcare.
South African health minister Aaron Motsoaledi wants India to hang tough on intellectual property (IP) challenges for pharmaceuticals because the country's role as a major supplier of affordable medicines needs to be lauded, not scolded.
Roche designated Aiea, HI's Diagnostic Laboratory Services a Molecular Center of Excellence for the next 5 years, granting the lab its latest diagnostic technology.
Google has been inking deals to expand its reach in patient monitoring and wearable health. In its latest foray the company will work with Dexcom to develop cheaper, miniaturized glucose monitors, combining its electronics platform with Dexcom's sensor technology to improve care for patients.
MedImmune on Monday announced a development deal worth up to $727 million--$27 million upfront--to acquire exclusive rights to Inovio Pharmaceuticals' HPV cancer vaccine INO-3112 and to develop additional cancer vaccine candidates.
Aerie Pharmaceuticals will use GrayBug's microparticle-based technologies to deliver its candidates to the front and back of the eye under a just-announced one-year research collaboration and licensing agreement. In particular Aerie is seeking to add sustained-release capabilities to its arsenal.
Three days ago Sanofi expanded its tight R&D relationship with Evotec to take on cell-replacement treatments for diabetes. And the pharma giant picked up this morning where it left off, adding an immuno-oncology pact with Evotec that also brings Austria's Apeiron Biologics into the mix.
U.S.-based proton therapy system maker Mevion Medical Systems has secured as much as $200 million in financing led by two Chinese Investors, HOPU Investments and YuanMing Capital.
Second-quarter earnings from nearly all multinationals showed a drop in business in China from double-digit paces in recent years blamed on tough tender and reimbursement policies and domestic competition as well as an economic slowdown.
AstraZeneca's big MedImmune subsidiary has nailed down its third pact in 5 days, inking a collaboration with Inovio Pharmaceuticals on a cancer vaccine designed to generate a tumor-specific T cell response. MedImmune is handing over a $27.5 million upfront and up to $700 million in milestones for the deal while agreeing to also cover the research tab.